Merus N.V. (NASDAQ:MRUS), a biotechnology company specializing in innovative antibody-based therapies with a market ...

Uncover the systematic approach to biotech firm valuation using DCF. Equip yourself with the knowledge to gauge company ...

Regeneron (NASDAQ:REGN) Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex landscape of challenges and opportunities in ...

The next article I wanted to discuss for the Biotech Analysis Central Model 10+ Portfolio Old Pick #17 is a biotech by the name of Tempest Therapeutics (TPST). I want to state that I have chosen to ...

The next article I wanted to discuss for the Biotech Analysis Central Model 10+ Portfolio Old Pick #2 is a biotech by the name of Arrowhead Pharmaceuticals (ARWR). The reason why I want to go over ...

The "Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2025" report has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive listing of all ...

LONDON (Reuters) -Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling through a prolonged downturn, increasing concerns they will ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

A Price to Earnings ratio of 30.09 significantly below the industry average by 0.52x suggests undervaluation. This can make the stock appealing for those seeking growth. With a Price to Book ratio of ...

NEW YORK (Reuters) -Large deals involving pharmaceutical and biotech companies are stalling as executives grapple with mercurial White House economic policies that have roiled markets and set off a ...